Baxter Healthcare Corporation. Announcement to directors
of pharmacy: Intralipid IV fat emulsion now available in plastic
containers. Baxter Healthcare Corporation,February26, 2004.
4.
Driscoll DF. Examination of selection of light-scattering and
light-obscuration acceptance criteria for lipid injectable emulsions.
Pharm Forum.2004
;30:2244–
2253.
Toce SS, Keenan WJ. Lipid intolerance in newborns is associated
with hepatic dysfunction but not infection. Arch Pediatr Adolesc
Med.1995;149:1249–
1253.
7.
Driscoll DF, Ling PR, Bistrian BR. Hepatic responses following
infusion of pharmaceutically unstable lipid injectable emulsions as all-in-one
mixtures into rats. Clin Nutr.2006
;25:842–
850.
8.
Driscoll DF, Ling PR, Bistrian BR. Hepatic indicators of oxidative
stress and tissue damage following a 24-hour infusion of an unstable
all-in-one (AIO) in rats. In: 28th ESPEN
Congress;October19–22,2006
; Istanbul Turkey. Abstract P0219.
9.
Driscoll DF, Martin C, Dumas G, et al. Incidence of
hypertriglyceridemia in critically ill neonates receiving lipids in glass
vs. plastic containers: a retrospective analysis. In:
28th ESPEN Congress; October19–22
, 2006; Istanbul, Turkey. Abstract
LB51.
10.
Driscoll DF, Martin C, Dumas G, et al. Incidence of
hypertriglyceridemia in critically ill neonates receiving lipids in glass vs.
plastic containers: a retrospective analysis [abstract]. JPEN J
Parenter Enteral Nutr.2007
;31: S16.
Abstract 025.
Barber TA. Pharmaceutical Particulate Matter: Analysis
and Control. Buffalo Grove, IL: Interpharm Press;1993
.
13.
Driscoll DF, Etzler F, Barber TA, Nehne J, Niemann W, Bistrian BR.
Physicochemical assessments of parenteral lipid emulsions: light obscuration
versus laser diffraction. Int J Pharm.2001
;219:21–
37.
14.
Driscoll DF, Bhargava HN, Li L, Zaim RH, Babayan VK, Bistrian BR.
The physicochemical stability of complex intravenous lipid dispersions as
total nutrient admixtures. Am J Hosp Pharm.1995
;52:623–
634.
15.
Tu YH, Knox NL, Biringer JM, Eichman ML, Schweinsberg PD, Howard
JR. Compatibility of iron dextran with total nutrient admixtures.
Am J Hosp Pharm.1992
;49:2233–
2235.
16.
Mirtallo J, Canada T, Johnson D, et al; Task Force for the Revision
of Safe Practices for Parenteral Nutrition. Safe practices for parenteral
nutrition. JPEN J Parenter Enteral Nutr.2004
;28:S39–
S70. Errataum 2006;30:177.
17.
National Advisory Group on Standards and Practice Guidelines for
Parenteral Nutrition. Safe practices for parenteral nutrition formulations.
JPEN J Parenter Enteral Nutr.1998
;22:49–
66.
18.
Chapter <797>. Pharmaceutical Compounding: Sterile
Preparations: Physical Tests: United States Pharmacopeia 29/National Formulary
24. Rockville, MD: United States Pharmacopeial Convention, Inc;2006
: 2735–2751.
19.
Driscoll DF. Stability and compatibility assessment techniques for
total parenteral nutrition admixtures: setting the bar according to
pharmacopeial standards. Curr Opin Clin Nutr.2005
;8:297–
303.
20.
Driscoll DF, Silvestri AP, Nehne J, Klütsch K, Bistrian BR,
Niemann W. The physicochemical stability of highly concentrated total nutrient
admixtures (TNAs) intended for fluid-restricted patients. Am J
Health Syst Pharm.2006;63:79–
85.
21.
Driscoll DF, Parikh M, Silvetsri AP, Klütsch K, Bistrian BR,
Nehne J. Establishing a stability window for MCT-LCT lipid based parenteral
nutrition: applying pharmacopeial standards. Am J Health Syst
Pharm.2006;63:2135–
2143.
22.
Driscoll DF, Silvestri AP, Mikrut BA, Bistrian BR. Stability of
adult-based total nutrient admixtures with soybean oil-based lipid injectable
emulsions: the effect of glass versus plastic packaging.
Am J Health Syst Pharm.2007
;64:396–
403.
23.
Driscoll DF, Ling PR, Bistrian BR. Physical stability of 20% lipid
injectable emulsions via simulated syringe infusion: effects of glass
vs. plastic product packaging. JPEN J Parenter Enteral
Nutr.2007;31:148–
153.
